Drugs / Red Vine Leaf Extract
Red Vine Leaf Extract
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02191241 | Aug 2001 → Sep 2004 | — | Boehringer Ingelheim | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT00855179 Comparator | Mar → Nov 2009 | venous insufficiency | Boehringer Ingelheim | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Red Vine Leaf Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02191241 ↗ |
| Known as | Antistax | “The aim of this study was to investigate the effect of a red-vine-leaf extract (AS195, Antistax(®), Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany) on the volume...” PMID 21239190 ↗ Jan 20111“1,800 mg Red Vine Leaf Extract (Antistax®)” NCT02191241 ↗ |
| Known as | AS 195 | “The aim of this study was to investigate the effect of a red-vine-leaf extract (AS195, Antistax(®), Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany) on the volume...” PMID 21239190 ↗ Jan 20111“Red vine leaf extract (AS 195)” NCT00855179 ↗ |
| Route | Oral | “720 mg/Day Orally” NCT00855179 ↗ |